Awardee OrganizationSCRIPPS RESEARCH INSTITUTE, THE
Description
Abstract Text
Relapse vulnerability is a challenge for the successful treatment of alcohol use disorder (AUD), making relapse
prevention a central focus of treatment and medication development efforts. Stress is a major factor that
contributes to the chronic relapsing and compulsive nature of drug addiction. The hypocretin (Hcrt; orexin)
system regulates physiological processes including feeding, energy metabolism, arousal, and stress, and is
recruited by alcohol. Hypocretin neurons are only located in the hypothalamus (HYP) that includes the lateral
HYP (LH), dorsomedial HYP (DMH), and perifornical area (PFA) and project to major components of
neurocircuitry that mediates drug seeking including the medial prefrontal cortex (mPFC). Chronic drug use
dysregulates stress responses that are mediated by corticotropin-releasing factor (CRF) in both the
hypothalamic-pituitary-adrenal (HPA) axis and extrahypothalamic brain stress areas outside the HPA axis (e.g.,
central nucleus of the amygdala [CeA] and bed nucleus of the stria terminalis [BNST]). An Hcrt/CRF interaction
exists that could participate in chronic relapsing and negative affective states that characterize drug addiction.
Dynorphin (Dyn) promotes depressive-like behavior and mediates the aversive effects of stress via k opioid
receptors (KORs) signaling. Even though Hcrt and Dyn are co-localized and co-released, in the ventral tegmental
area (VTA) and the paraventricular nucleus of the thalamus (PVT), they play opposing roles in the mediation of
drug-directed behavior. The Martin-Fardon component will test whether Hcrt/CRF and Hcrt/Dyn interaction in the
infralimbic cortex (IL) -- a subregion of the mPFC that exerts inhibitory control over alcohol seeking and shows
long-term deficits in rats following a history of alcohol dependence -- changes following dependence and whether
these systems are pivotal in stress-induced reinstatement of alcohol-seeking behavior in male and female rats
at late (2 weeks) abstinence. This will be achieved by (1) exploring whether the Hcrt/CRF and Hcrt/Dyn
interactions in the IL mediate stress-induced reinstatement of alcohol-seeking behavior in alcohol-dependent
animals during abstinence; (2) establishing whether the IL Hcrt-r/CRF1/KOR signaling in the IL is upregulated
due to alcohol-dependence during abstinence; and (3) confirming the importance of the HYP(Hcrt)®IL circuit
during stress-induced reinstatement of alcohol-seeking behavior using an inhibitory Designer Receptor
Exclusively Activated by Designer Drugs construct selective for Orx cells in Orx-Cre rats. This project will provide
insights into the involvement of the IL Hcrt-r/CRF1/KOR signaling during pathological (alcohol-seeking) behavior
and may identify novel targets for alcohol craving and relapse prevention.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AbstinenceAlcohol consumptionAlcohol dependenceAlcoholismAlcoholsAmygdaloid structureAnimal ModelAnimalsAreaArousalBehaviorBrainCRF receptor type 1Cell NucleusCellsCellular NeurobiologyChronicCollaborationsComplementCorticotropin-Releasing HormoneCorticotropin-Releasing Hormone ReceptorsDarknessDependenceDevelopmentDrug AddictionDrug usageDynorphinsEnergy MetabolismFDA approvedFemaleFundingGene ExpressionGeneticHypothalamic structureLateralMedialMediatingMediationMolecularNatureNeuronsNeuropeptidesNeuropharmacologyORL1 receptorOpioid ReceptorPathologicPharmaceutical PreparationsPhysiological ProcessesPlayPrefrontal CortexRattusReceptor SignalingRecording of previous eventsRelapseRoleSideSignal TransductionStressStructure of paraventricular nucleus of thalamusStructure of terminal stria nuclei of preoptic regionSystemTestingVentral Tegmental AreaWorkalcohol abuse therapyalcohol cravingalcohol effectalcohol relapsealcohol seeking behavioralcohol use disorderantagonistbiological adaptation to stressdepressive symptomsdesigner receptors exclusively activated by designer drugsfeedinghypocretinhypothalamic-pituitary-adrenal axisinsightmalemetabotropic glutamate receptor 3negative affectneural circuitneuroproteomicsnociceptinnovelreceptorrecruitrelapse preventionresponsetransmission process
National Institute on Alcohol Abuse and Alcoholism
CFDA Code
DUNS Number
781613492
UEI
PHZJFZ32NKH4
Project Start Date
01-December-1983
Project End Date
31-December-2027
Budget Start Date
01-January-2024
Budget End Date
31-December-2024
Project Funding Information for 2024
Total Funding
$219,629
Direct Costs
$129,805
Indirect Costs
$89,824
Year
Funding IC
FY Total Cost by IC
2024
National Institute on Alcohol Abuse and Alcoholism
$219,629
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P60AA006420-41 5138
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P60AA006420-41 5138
Patents
No Patents information available for 5P60AA006420-41 5138
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P60AA006420-41 5138
Clinical Studies
No Clinical Studies information available for 5P60AA006420-41 5138
News and More
Related News Releases
No news release information available for 5P60AA006420-41 5138
History
No Historical information available for 5P60AA006420-41 5138
Similar Projects
No Similar Projects information available for 5P60AA006420-41 5138